Results 71 to 80 of about 53,202 (260)

Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists

Diabetes & Vascular Disease Research
The newfound knowledge in type 2 diabetes (T2D) during the past decade for the sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is wealthy in favorable results for key patient-important outcomes ...
Kyriakos Kintzoglanakis, Christos Diamantis, Anargiros Mariolis, Stavroula A Paschou   +3 more
doaj   +1 more source

Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment (OPTIC)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity. Materials and Methods US adults with obesity or overweight and ≥ 1 obesity‐related complication completed an online survey including a discrete‐choice experiment (DCE) in October–November ...
Jaime P. Almandoz, Beverly G. Tchang, Kelley Myers, Andrea Traina, Jigish Bhavsar, Victoria Divino, Cannon Kent, Sara Tadesse Bell   +7 more
wiley   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Ankle Fracture Open Reduction and Internal Fixation

Foot & Ankle Orthopaedics
Research Type: Level 3 - Retrospective cohort study, Case-control study, Meta-analysis of Level 3 studies Introduction/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are quickly growing in popularity as effective tools in the management of ...
Joshua Morningstar BS, Bradley Lauck BA, Nicholas Bank MD, Trapper Lalli MD   +3 more
doaj   +1 more source

Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the effect of semaglutide on body composition and physical function. Materials and Methods The phase 3b STEP UP trial randomised adults with body mass index ≥ 30 kg/m2 to once‐weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg or placebo for 72 weeks.
Jøran Hjelmesæth, Suhas Bhat, W. Timothy Garvey, Kristoffer Jensen Kolnes, Jennifer Linge, Ildiko Lingvay, Niklas Kahr Rasmussen, Julio Rosenstock, Sean Wharton   +8 more
wiley   +1 more source

Sex and Socioeconomic Differences in the Initiation of SGLT2 Inhibitors and GLP‐1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Nationwide Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardioprotective glucose‐lowering drugs (GLDs) remain underutilised in individuals with Type 2 diabetes (T2D) and cardiovascular disease (CVD). We aimed to estimate the association between sex and socioeconomic status and initiation of cardioprotective GLDs and to identify factors associated with non‐initiation of cardioprotective GLDs ...
Elena Calderon, Lasse Bjerg, Anders A. Isaksen, Annelli Sandbæk, Kristian L. Funck, Erik L. Grove   +5 more
wiley   +1 more source

A Clinical Practice Guideline for Managing Gastrointestinal Toxicities Related to GLP-1RA and GIP/GLP-1RA Medications [PDF]

The project is a Clinical Practice Guideline (CPG) for managing Gastrointestinal (GI) toxicities related to Glucagon-like Peptide-Receptor Agonist 1 (GLP-1RA) and Glucose-dependent insulinotropic polypeptide/Glucagon-like peptide-1Receptor Agonist (GIP ...
Williamson, Lindsay
core   +1 more source

GLP-1RA code file

Python code used for data analysis of GLP-1RA case listings extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS). 'drug' was altered for each GLP1RA of interest and control to extract relevant data.
Murray, Mya
core   +1 more source

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea

, 2023
Bile acid diarrhea (BAD) is a socially debilitating disease. Typical symptoms include loose stools, urgency, and high stool frequency. Recently, we reported the superior efficacy of the glucagon like-peptide 1 receptor agonist (GLP-1RA) liraglutide ...
Knudsen, Elisabeth, Knop, Filip Krag, Kårhus, Martin Lund   +2 more
core   +1 more source

Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis).
Frances Perry, Silvia J. Leon, Kate Polecina, Ruth Getachew, Nicole Askin, Thomas Ferguson, Reid Whitlock, Zihe Zheng, Carolina Aldworth, Arvind Katta, Jacob Earl, Mauricio Beller Ferri, Navdeep Tangri   +12 more
wiley   +1 more source

Use of GLP-1 receptor agonists and risks of suicide attempts or self-harm in patients with type 2 diabetes: a multicountry self-control case series study

BMJ Mental Health
Background Inconclusive findings regarding the association between suicidal ideation/suicide attempt and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been recently revealed in a small number of studies.Methods This was a multinational self ...
Ian Chi Kei Wong, Eric Yuk Fai Wan, Huang-Tz Ou, Esther Wai Yin Chan, Vincent Ka Chun Yan, Zi-Yang Peng, Vincent Kai Chung Wong   +6 more
doaj   +1 more source